• Catalog Number:

  E1KS1195

• Amount:

  5mg1​ PHYSICAL AND CHEMICAL PROPERTIES

• Storage/Stability:

  -20℃ 2 years

2​ Biological Activity The progression and growth of prostate cancer cells requires the production of testosterone.While existing therapies target testosterone production in the testes, it is also secreted by cells in the adrenal cortex. TAK-700 is an oral, selective, non-steroidal androgen synthesis inhibitor of the 17,20 lyase, which is a key enzyme in the production of steroidal hormones. [1] In preclinical studies, TAK-700 has been shown to bind to and inhibit the enzyme 17,20 lygase in both the testes and adrenal glands. TAK-700 is currently under clinical Phase III studies for metastatic, hormone-refractory prostate cancer. . [1] 3​ References: The pharmacological and toxicological properties of this product have not been fully investigated. Exercise caution in use and handling. This product must not be used in humans.